INDOCO258.00

Indoco Remedies Limited

· Pharma & Health
₹ CrorePeersSAIPARENTPANACEABIOHIKALWINDLASHESTERBIODCALSYNCOMFSOLARAMcap ₹2,381 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity8.87-7.24-10.21-10.21
Return on Assets4.52-3.21-3.81-3.81
Return on Capital Employed9.95-0.901.001.00
Return on Invested Capital6.19-0.730.730.70
Margins
EBITDA Margin13.445.967.688.82
Operating Margin8.39-0.880.830.83
Incremental Operating Margin109.6116.59
Pretax Margin7.47-4.47-5.770.42
Net Income Margin5.34-4.68-5.350.17
Net Income to Common Margin5.42-4.43-5.160.30
FCF Margin-14.89-15.692.422.42
Additional
Effective Tax Rate28.56-4.817.3360.66
Dvd Payout Ratio21.35-17.83-1.94
Sustainable Growth Rate6.98-8.53-10.41-10.21
Incremental Operating Margin %109.6116.5967.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.